What a pain in the … back: a review of current treatment options with a focus on naproxen sodium
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.ABSTRACTNon-specific low back pain (LBP) represents a challenging and prevalent condition that is one of the most common symptoms leading to primary care physician visits. While established guidelines recommend prioritizing non-pharmacological approaches as the primary course of action, pharmacological treatments are advised when non-pharmacological approaches are ineffective or based on patient preference. These guidelines recommend non-steroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxers (SMRs) as the first-line pharm...
Source: J Pharm Pharm Sci - February 22, 2024 Category: Drugs & Pharmacology Authors: Steven M Weisman Giovanni Ciavarra Grant Cooper Source Type: research
What a pain in the … back: a review of current treatment options with a focus on naproxen sodium
J Pharm Pharm Sci. 2024 Feb 7;27:12384. doi: 10.3389/jpps.2024.12384. eCollection 2024.ABSTRACTNon-specific low back pain (LBP) represents a challenging and prevalent condition that is one of the most common symptoms leading to primary care physician visits. While established guidelines recommend prioritizing non-pharmacological approaches as the primary course of action, pharmacological treatments are advised when non-pharmacological approaches are ineffective or based on patient preference. These guidelines recommend non-steroidal anti-inflammatory drugs (NSAIDs) or skeletal muscle relaxers (SMRs) as the first-line pharm...
Source: J Pharm Pharm Sci - February 22, 2024 Category: Drugs & Pharmacology Authors: Steven M Weisman Giovanni Ciavarra Grant Cooper Source Type: research
A big leap in prescription drug promotion in Canada
J Pharm Pharm Sci. 2024 Jan 24;27:12666. doi: 10.3389/jpps.2024.12666. eCollection 2024.NO ABSTRACTPMID:38333596 | PMC:PMC10847252 | DOI:10.3389/jpps.2024.12666 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - February 9, 2024 Category: Drugs & Pharmacology Authors: Catherine Y Lau Source Type: research
A big leap in prescription drug promotion in Canada
J Pharm Pharm Sci. 2024 Jan 24;27:12666. doi: 10.3389/jpps.2024.12666. eCollection 2024.NO ABSTRACTPMID:38333596 | PMC:PMC10847252 | DOI:10.3389/jpps.2024.12666 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - February 9, 2024 Category: Drugs & Pharmacology Authors: Catherine Y Lau Source Type: research
A big leap in prescription drug promotion in Canada
J Pharm Pharm Sci. 2024 Jan 24;27:12666. doi: 10.3389/jpps.2024.12666. eCollection 2024.NO ABSTRACTPMID:38333596 | PMC:PMC10847252 | DOI:10.3389/jpps.2024.12666 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - February 9, 2024 Category: Drugs & Pharmacology Authors: Catherine Y Lau Source Type: research
A big leap in prescription drug promotion in Canada
J Pharm Pharm Sci. 2024 Jan 24;27:12666. doi: 10.3389/jpps.2024.12666. eCollection 2024.NO ABSTRACTPMID:38333596 | PMC:PMC10847252 | DOI:10.3389/jpps.2024.12666 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - February 9, 2024 Category: Drugs & Pharmacology Authors: Catherine Y Lau Source Type: research
A big leap in prescription drug promotion in Canada
J Pharm Pharm Sci. 2024 Jan 24;27:12666. doi: 10.3389/jpps.2024.12666. eCollection 2024.NO ABSTRACTPMID:38333596 | PMC:PMC10847252 | DOI:10.3389/jpps.2024.12666 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - February 9, 2024 Category: Drugs & Pharmacology Authors: Catherine Y Lau Source Type: research
A big leap in prescription drug promotion in Canada
J Pharm Pharm Sci. 2024 Jan 24;27:12666. doi: 10.3389/jpps.2024.12666. eCollection 2024.NO ABSTRACTPMID:38333596 | PMC:PMC10847252 | DOI:10.3389/jpps.2024.12666 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - February 9, 2024 Category: Drugs & Pharmacology Authors: Catherine Y Lau Source Type: research
Effect of Oregon grape root extracts on P-glycoprotein mediated transport in < em > in vitro < /em > cell lines
Conclusion: Our study showed that Oregon grape root extracts modulated P-glycoprotein, thereby may affect the bioavailability of drugs that are substrates of P-glycoprotein.PMID:38304488 | PMC:PMC10830684 | DOI:10.3389/jpps.2023.11927 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - February 2, 2024 Category: Drugs & Pharmacology Authors: Ying Fan Zhu Zhou Lei Zhang Source Type: research
Comparing broad and narrow phenotype algorithms: differences in performance characteristics and immortal time incurred
Conclusion: Attempting to increase the specificity of a health condition algorithm by adding a second code is a potentially valid approach to increase specificity, albeit at the cost of incurring immortal time.PMID:38235322 | PMC:PMC10791821 | DOI:10.3389/jpps.2023.12095 (Source: J Pharm Pharm Sci)
Source: J Pharm Pharm Sci - January 18, 2024 Category: Drugs & Pharmacology Authors: Joel N Swerdel Mitchell M Conover Source Type: research
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials
J Pharm Pharm Sci. 2023 Dec 20;26:11892. doi: 10.3389/jpps.2023.11892. eCollection 2023.ABSTRACTHyperkalemia is a common electrolyte disorder in patients with chronic kidney disease (CKD) that increases in prevalence with the decline of glomerular fltration rate (GFR). Another risk of hyperkalemia is the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and/or mineralocorticoid receptor antagonists (MRAs) in managing CKD and proteinuria. The treatment of chronic hyperkalemia is challenging especially for outpatients. Treatment options for hyperkalemia include the potassium exchange resins of which two new pota...
Source: J Pharm Pharm Sci - January 4, 2024 Category: Drugs & Pharmacology Authors: Jaclyn Gruver Akram Al-Makki Brian Shepler Source Type: research
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials
J Pharm Pharm Sci. 2023 Dec 20;26:11892. doi: 10.3389/jpps.2023.11892. eCollection 2023.ABSTRACTHyperkalemia is a common electrolyte disorder in patients with chronic kidney disease (CKD) that increases in prevalence with the decline of glomerular fltration rate (GFR). Another risk of hyperkalemia is the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and/or mineralocorticoid receptor antagonists (MRAs) in managing CKD and proteinuria. The treatment of chronic hyperkalemia is challenging especially for outpatients. Treatment options for hyperkalemia include the potassium exchange resins of which two new pota...
Source: J Pharm Pharm Sci - January 4, 2024 Category: Drugs & Pharmacology Authors: Jaclyn Gruver Akram Al-Makki Brian Shepler Source Type: research
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials
J Pharm Pharm Sci. 2023 Dec 20;26:11892. doi: 10.3389/jpps.2023.11892. eCollection 2023.ABSTRACTHyperkalemia is a common electrolyte disorder in patients with chronic kidney disease (CKD) that increases in prevalence with the decline of glomerular fltration rate (GFR). Another risk of hyperkalemia is the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and/or mineralocorticoid receptor antagonists (MRAs) in managing CKD and proteinuria. The treatment of chronic hyperkalemia is challenging especially for outpatients. Treatment options for hyperkalemia include the potassium exchange resins of which two new pota...
Source: J Pharm Pharm Sci - January 4, 2024 Category: Drugs & Pharmacology Authors: Jaclyn Gruver Akram Al-Makki Brian Shepler Source Type: research
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials
J Pharm Pharm Sci. 2023 Dec 20;26:11892. doi: 10.3389/jpps.2023.11892. eCollection 2023.ABSTRACTHyperkalemia is a common electrolyte disorder in patients with chronic kidney disease (CKD) that increases in prevalence with the decline of glomerular fltration rate (GFR). Another risk of hyperkalemia is the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and/or mineralocorticoid receptor antagonists (MRAs) in managing CKD and proteinuria. The treatment of chronic hyperkalemia is challenging especially for outpatients. Treatment options for hyperkalemia include the potassium exchange resins of which two new pota...
Source: J Pharm Pharm Sci - January 4, 2024 Category: Drugs & Pharmacology Authors: Jaclyn Gruver Akram Al-Makki Brian Shepler Source Type: research
Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials
J Pharm Pharm Sci. 2023 Dec 20;26:11892. doi: 10.3389/jpps.2023.11892. eCollection 2023.ABSTRACTHyperkalemia is a common electrolyte disorder in patients with chronic kidney disease (CKD) that increases in prevalence with the decline of glomerular fltration rate (GFR). Another risk of hyperkalemia is the use of renin-angiotensin-aldosterone system inhibitors (RAASi) and/or mineralocorticoid receptor antagonists (MRAs) in managing CKD and proteinuria. The treatment of chronic hyperkalemia is challenging especially for outpatients. Treatment options for hyperkalemia include the potassium exchange resins of which two new pota...
Source: J Pharm Pharm Sci - January 4, 2024 Category: Drugs & Pharmacology Authors: Jaclyn Gruver Akram Al-Makki Brian Shepler Source Type: research
